Blood Clues: How Platelet Chemistry Could Transform Ovarian Cancer Detection

Ovarian cancer has long been one of medicine’s most frustrating adversaries. Often called a silent killer, it typically announces itself only after it has spread beyond the ovary, when treatment options narrow and survival odds collapse. According to the latest GLOBOCAN 2024 estimates, roughly 324,000 women worldwide were diagnosed with the disease in 2024, and about 207,000 died from it. In Western countries it ranks as the fifth leading cause of cancer-related death among women, and the ten-year survival rate for advanced-stage disease has remained stubbornly fixed at around 10 to 15 percent for two decades. A new open-access review published in Molecular Biology Reports argues that a surprising ally in the fight against this disease may be hiding in plain sight: the blood platelet, the tiny cell fragment best known for stopping bleeds.

The review, authored by Joanna Kirmuć and Karol Kramkowski of the Medical University of Białystok together with gynecologic oncologist Marcin Jóźwik, synthesizes evidence connecting oxidative stress, chronic inflammation, and platelet activation with ovarian cancer progression. Its central thesis is that platelet-derived lipid messengers, particularly thromboxane B2, the stable metabolite of the potent platelet aggregator thromboxane A2, deserve systematic investigation as biomarkers that could complement the flawed diagnostic tools currently in clinical use. The authors are careful to stress that the clinical utility of these molecules remains unproven, but they make a compelling mechanistic case for why the field should pay attention.

To understand the argument, it helps to grasp why existing diagnostics fall short. The workhorses of ovarian cancer detection are two proteins, CA125 and HE4, often combined with menopausal status in the Risk of Ovarian Malignancy Algorithm, or ROMA. CA125, a mucin known as MUC16, rises above the conventional threshold of 35 units per milliliter in many epithelial ovarian cancers, but it also climbs during menstruation, pregnancy, endometriosis, inflammatory bowel disease, and unrelated malignancies. HE4, encoded by the WFDC2 gene, is more specific and elevated across all disease stages, yet its performance varies by histological subtype. ROMA improves specificity over either marker alone, but it cannot reliably gauge tumor aggressiveness or detect metastases, and neither marker nor any combination of them has proven accurate enough for population-level screening.

The stakes of this diagnostic gap are enormous. Stage I ovarian cancer carries cure rates of up to 90 percent, yet only about 20 percent of cases are caught that early. Large randomized screening trials, including the UK Collaborative Trial of Ovarian Cancer Screening and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, tested multimodal strategies combining ultrasound, longitudinal CA125 algorithms, and emerging molecular markers, and none demonstrated a meaningful reduction in mortality. Ultrasound is operator-dependent and can miss early lesions, while CA125 lacks the specificity needed to distinguish cancer from benign inflammation. The field, in short, needs biomarkers that capture the dynamic biology of the tumor rather than merely its bulk.

This is where platelets enter the picture. Cancer and coagulation are deeply intertwined. Tumor cells express tissue factor, shed tissue factor-positive extracellular vesicles, and activate the coagulation cascade to generate thrombin. Thrombin then activates platelets through protease-activated receptors, triggering phospholipase A2, the release of arachidonic acid from membrane phospholipids, and the cyclooxygenase-1-dependent synthesis of thromboxane A2, which is rapidly hydrolyzed to measurable thromboxane B2. Experimental studies in ovarian cancer have shown that platelet-tumor cell interactions enhance tissue factor expression, promote metastatic cell phenotypes, and drive cancer cell migration. Activated platelets form aggregates with tumor cells, creating a protective shield that facilitates immune evasion and dissemination, with receptors such as glycoprotein VI and C-type lectin-like receptor 2 mediating recognition of matrix components and podoplanin-expressing tumor cells.

The eicosanoid system that platelets draw upon is a sprawling lipid signaling network with three main branches. Arachidonic acid released by phospholipase A2 is metabolized through cyclooxygenase, lipoxygenase, and cytochrome P450 pathways, yielding prostaglandins, thromboxanes, hydroxyeicosatetraenoic acids, and other mediators. In cancer, this network tilts toward tumor promotion. Thromboxane A2 and prostaglandin E2 drive pro-tumor signaling, while lipoxygenase-derived HETEs such as 12-HETE and 15-HETE are associated with inflammation, invasion, and tumor progression. Meanwhile, prostacyclin, produced mainly by vascular cells, exerts opposing vasodilatory and anti-aggregatory effects, and the balance between thromboxane A2 and prostacyclin is pivotal for vascular homeostasis. In cancer and chronic inflammation, platelet activity often becomes excessive, disrupting that balance and potentially fueling angiogenesis and metastatic spread.

Oxidative stress provides a further mechanistic thread linking these pathways. Reactive oxygen species damage DNA, proteins, and lipids, promoting genomic instability, but they also activate phospholipase A2 directly, increasing arachidonic acid release and amplifying thromboxane synthesis within platelets. Cancer cells adapt by bolstering antioxidant defenses and co-opting redox-sensitive signaling cascades such as MAPK, JNK, and NF-kappaB to enhance survival and proliferation. Chronic pelvic inflammation, including the inflammatory-like event of ovulation itself with its bursts of chemokines, growth factors, and reactive oxygen species, may contribute to repeated carcinogenic exposure. Cytokines such as interleukin 6, tumor necrosis factor alpha, and interleukin 8 promote tumor growth, immune evasion, and therapeutic resistance, and elevated interleukin 6 correlates with advanced disease and poorer outcomes. Inflammation also enhances platelet activation and thromboxane biosynthesis, closing the loop between the tumor microenvironment and platelet-derived eicosanoids.

What does the actual clinical evidence on thromboxane B2 in ovarian cancer show? Early studies from the 1980s reported elevated thromboxane B2 levels in patients with gynecological malignancies, and in-vitro work suggested that a predominance of thromboxane A2 may contribute to tumor growth and dissemination. One study found thromboxane B2 levels significantly higher in metastatic ovarian cancer tissue than in localized tumors, borderline malignant tumors, benign lesions, or normal tissue. Evidence from colorectal and lung adenocarcinoma supports the biological relevance of thromboxane metabolites in cancer-associated platelet activation, and a substudy of the Add-Aspirin trial linked 11-dehydro-thromboxane B2 levels to tumor characteristics in gastrointestinal cancers. Yet the ovarian data are decades old, were never systematically stratified by FIGO stage, histological subtype, treatment response, or survival, and never established sensitivity, specificity, AUC values, or validated cut-offs. The authors identify this as a striking knowledge gap: no recent studies from the past two decades have specifically investigated eicosanoid profiles in ovarian cancer patients.

Measurement technology, however, has advanced considerably. Thromboxane B2 can be quantified by enzyme-linked immunosorbent assay, gas chromatography, or high-performance liquid chromatography, but liquid chromatography-mass spectrometry is increasingly preferred because it simultaneously quantifies multiple eicosanoids with high precision from small sample volumes of plasma or urine, enabling minimally invasive sampling. Recent lipidomic studies have identified distinct circulating lipid signatures in ovarian cancer patients, with alterations in phospholipids, ceramides, sphingomyelins, and triacylglycerols detectable even in early-stage disease. The authors propose that a multiplex panel integrating CA125, HE4, and selected platelet- and inflammation-derived lipid mediators, including thromboxane B2, prostacyclin metabolites, and lipoxygenase-derived HETEs, could improve discrimination between benign inflammatory conditions and early-stage epithelial ovarian cancer while offering insight into tumor aggressiveness that conventional markers cannot provide.

There are important caveats, and the review does not shy away from them. Thromboxane B2 is not cancer-specific; it reflects thromboxane biosynthesis from any source, including inflammatory cells, and must be interpreted as a marker of platelet activation rather than of malignancy itself. Routine implementation of LC-MS eicosanoid profiling faces hurdles of instrumentation cost, specialized infrastructure, and the absence of standardized analytical protocols. Intriguingly, the platelet connection also has therapeutic implications: epidemiological evidence suggests regular aspirin use, which irreversibly inhibits platelet COX-1, may modestly reduce ovarian cancer risk, though the evidence remains insufficient to recommend aspirin for primary prevention. The authors call for prospective studies in adequately powered cohorts spanning healthy individuals, benign gynecological conditions, and diverse ovarian cancer stages and subtypes, with standardized procedures and clinically relevant cut-off values. If those studies succeed, the humble platelet, long a bit player in oncology, could become a central informant in detecting one of medicine’s deadliest cancers before it is too late.

Subject of Research: Platelet activation and eicosanoid signaling as potential biomarkers in ovarian cancer

Article Title: Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development

Article References: Kirmuć, J., Jóźwik, M., & Kramkowski, K. (2026). Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development. Molecular Biology Reports, 53(1), Article 1664. https://doi.org/10.1007/s11033-026-12848-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12848-x

Keywords: ovarian cancer, platelets, thromboxane B2, eicosanoids, biomarkers, CA125, HE4, ROMA algorithm, oxidative stress, inflammation, lipidomics, early detection